Novavax applies to the EMA for its Covid vaccine from age 12
The vaccine is designed to target the JN.1 lineage, with confirmed efficacy against currently circulating variants, including KP.2 and KP.3.
Preclinical data show that it induces polyfunctional and targeted immune responses, reinforcing its potential to respond to mutations and variants.
Novavax is also preparing submissions to the FDA and other global regulatory authorities, aiming to distribute its vaccine in single-dose vials upon approval.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction